| Shaojie Xu,Yiming Feng,Xingyin Li,Zaozao Huang,Hewei Li,Ganxin Wang. Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy. Oncol Transl Med, 2022, 8: 109-153. |
| Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy |
| Received:December 31, 2021 Revised:June 14, 2022 |
| View Full Text View/Add Comment Download reader |
| KeyWord:gastric cancer; programmed cell death receptor 1; γ-glutamyl transpeptidase (GGT); prognosis |
| Author Name | Affiliation | E-mail | | Shaojie Xu | Huazhong University of Science and Technology | u201712199@hust.edu.cn | | Yiming Feng | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Xingyin Li | Huazhong University of Science and Technology | | | Zaozao Huang | Yangchunhu Community Hospital, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology | huangzaozao1986@163.com | | Hewei Li | Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Ganxin Wang | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | |
|
| Hits: 3091 |
| Download times: 4232 |
| Abstract: |
| Objective Antibodies targeting programmed cell death protein 1 (PD-1) have become the mainstay of
treatment for chemotherapy-refractory gastric cancer, characterized by high levels of programmed cell
death ligand-1 (PDL-1) expression. However, the routine clinical implementation of PDL-1 testing is
currently limited by the lack of robust detection methods. In this regard, the role of plasma γ-glutamyl
transpeptidase (GGT), an N-terminal nucleophilic hydrolase, as an independent predictor of the efficacy of
anti-PD-1 therapy remains unknown. In this study, we aimed to assessed the prognostic role of changes in
plasma GGT levels (6 weeks vs. baseline) in patients with advanced gastric cancer treated with anti-PD-1
immunotherapy.
Methods We retrospectively analyzed data from 57 patients with gastric cancer treated with anti-PD-1
antibodies (camrelizumab, sintilimab, nivolumab, tislelizumab, and toripalimab) at the Union Hospital,
Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, from July 2018
to February 2021.
Results We found that after 6 weeks of treatment, there were significant differences between responders
and non-responders with respect to plasma GGT levels (P < 0.001). Multivariate logistic regression analysis
revealed that the continuous value of the 6-week difference in GGT levels (OR = 1.437, 95% CI = 1.116–
1.849, P = 0.005) and 6-week difference in GGT ≥ 0 or < 0 (OR = 53.675, 95% CI = 6.379–451.669,
P < 0.001) were independent predictors of disease control. Survival analysis indicated that a reduction
in plasma GGT6 levels during treatment was significantly associated with a favorable progression-free
survival (PFS) and overall survival (P < 0.001). Consistently, univariate and multivariate Cox regression
analyses revealed that a reduction in plasma GGT6 levels during treatment was an independent predictor
of PFS (HR = 1.033, 95% CI = 1.013–1.053, P = 0.001).
Conclusion Alterations in plasma GGT levels during treatment can be used as a predictor of disease
progression and survival in patients with advanced gastric cancer undergoing treatment with anti-PD-1
antibodies. |
| Close |
|
|
|